GenFleet rises most in 4 weeks on progress of GFH375 in cancer treatment
10/08/2026 08:21
BUZZ-GenFleet rises most in 4 weeks on progress of GFH375 in cancer treatment ** Shares of GenFleet Therapeutics (Shanghai) Inc 2595.HK rise 8.6% to HK$32.48, on course for their biggest one-day pct gain since July 15
** Stock hits the highest point since July 28 in the fifth consecutive session of gain
** China-based innovative drugs developer said its oral KRAS G12D inhibitor GFH375 for cancer treatment has advanced into a multicenter, open-label, randomized controlled registrational phase III study in China for evaluating monotherapy efficacy and safety
** YTD, stock up 34.4%, Hang Seng Biotech Index .HSBIO up 9%
(Reporting by Donny Kwok)
Recent news on GenFleet Therapeutics (Shanghai)
See all newsHK-listed GenFleet jumps on positive progress of cancer drug
GenFleet hits over 3-week high as cancer drug makes progress on BTD list
Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
HK-listed GenFleet rises most in a month on repurchasing shares
Brief: GenFleet Therapeutics (Shanghai) Reports Loss Of RMB220.17 Million For Six Months